Sigilon Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is developing a new class of therapeutics and functional cures for patients with chronic diseases by providing stable and durable levels of therapeutic molecules to patients. It's lead product candidate, SIG-001, prevents bleeding in patients with moderate-severe to severe Hemophilia A.